AzTrials
AzTrials

Opioid-Related DisordersPhase 4NCT02616523

Influence of Dexmedetomidine and Lidocaine on Opioid Consumption in Laparoscopic Intestine Resection

A Phase 4 study testing Dexmedetomidine, Lidocaine and Fentanyl in people with Opioid-Related Disorders and Neuralgia, run by University Medical Centre Ljubljana.

Completed

Finished. The study has ended and is not enrolling. Results may be posted on the official record.

Official record
Search all trials

Trial summary

Using combination of opioid analgesics and analgesics with different mechanism of action the investigators can decrease the consumption of opioid analgesics and their side effects. Read more about this study

Who is it for?
Ages 35 to 85 years
Conditions the study is for
Opioid-Related Disorders, Neuralgia
What is being tested?
Dexmedetomidine, Lidocaine and Fentanyl
Type of treatment
Injection or infusion
Could I receive a placebo?
Yes, some participants may receive a placebo
How many people
60 participants
Where
No sites listed yet
Study dates
Jul 2014to May 2016
Phase
Phase 4
Are there results?
Yes, posted in the registrySummary in the doctors' view

Key requirements

Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.

  • Ages 35 to 85 years
  • All sexes
  • No healthy volunteers
  • Adult, Older adult

Who may be able to join

  • patients aged 35 to 85,
  • ASA 2-3 (according to the classification of American Society of Anesthesiologists),
  • undergoing a planned laparoscopic intestine resection at the Department of Abdominal Surgery at the University Medical Centre Ljubljana.

Who cannot join

  • allergies to alpha 2 receptor agonists,
  • uncontrolled arterial hypertension,
  • 2nd and 3rd degree atrioventricular block,
  • alcohol and illegal drugs abusers,
  • patients with clinically important neurological, cardiovascular, respiratory (COPD, emphysema), renal, liver, and gastrointestinal disease,
  • pregnant women,
  • patients younger than 18 years-

About this study

Official title: Influence of Dexmedetomidine and Lidocaine on Opioid Consumption, Cognitive Function and Incidence of Neuropathic Pain in Laparoscopic Intestine Resection

Using combination of opioid analgesics and analgesics with different mechanism of action the investigators can decrease the consumption of opioid analgesics and their side effects. The investigators will use opioid analgesic fentanyl alone or in combination with dexmedetomidine or lidocaine.The participants scheduled for laparoscopic intestine resection will be divided in three groups: in the first group, the participants will receive single boluses of fentanyl, in the second group, the participants will receive continuous infusion of lidocaine and single boluses of fentanyl, and in the third group, the participants will receive continuous infusion of dexmedetomidine and single boluses of fentanyl. Participants with intraoperative infusion od dexmedetomidine or lidocaine will need less boluses of fentanyl during the operation and less opioid analgesics after the operation in comparison to those who will receive only fentanyl boluses. Better cognitive function after the operation is expected in participants receiving dexmedetomidine infusion. There will be minimal incidence of neuropathic pain because of minimal surgical injury of peripheral nerves in all groups of patients.

Read the detailed description

Introduction: The consumption of opioid analgetics and their side effects can be minimized by using the combination of opioid analgesics and analgesics with different mechanism of action. The investigators will use opioid analgesic fentanyl alone or in combination with dexmedetomidine or lidocaine. Dexmedetomidine is alpha 2 adrenergic receptor agonist and is used more and more during anesthesia because of its anesthetic and analgesic effects as it preserves mental status and decreases the consumption of analgesics. Lidocaine is a local anesthetic and antiarrhythmic drug which decreases opioid consumption as well.

The participants scheduled for laparoscopic intestine resection will be divided in three groups: in the first group, the participants will receive single boluses of fentanyl, in the second group, the participants will receive continuous infusion of lidocaine and single boluses of fentanyl, and in the third group, the participants will receive continuous infusion of dexmedetomidine and single boluses of fentanyl.

Hypothesis: Participants with intraoperative infusion od dexmedetomidine or lidocaine will need less boluses of fentanyl during the operation and less opioid analgesics after the operation in comparison to those who will receive only fentanyl boluses. Better cognitive function after the operation in participants receiving dexmedetomidine infusion is expected. There will be minimal incidence of neuropathic pain because of minimal surgical injury of peripheral nerves in all groups.

Justification: Lidocaine and dexmedetomidine are analgesics with different mechanism of action in comparison to opioid analgesics. Their use during the operation decreases the consumption of opioids intra- and postoperatively. Dexmedetomidine has beneficial effect on cognitive function and that is why the investigators expect preserved cognitive function in participants after the operation. Because of minimal surgical injury and, therefore, minimal probability of peripheral nerve injury, the investigators expect low incidence of neuropathic pain in all groups.

Methods: The investigators will include 60 participants in the study, between 35 to 85 years old, ASA 2 - 3 (American Society of Anesthesiologists, ASA) undergoing a planned laparoscopic intestine resection. The participants will be randomized into three groups. In the first group, fentanyl boluses will be adimistred during the operation, in the second, infusion of lidocaine will be added to fentanyl, and in the third, the infusion of dexmedetomidine will be added to fentanyl. The investigators will record opioid consumption during the operation and two days after the operation. The investigators will use mini mental test for evaluation of cognitive function before the operation and at the transfer of the participant postoperatively to the surgical ward, in order to explore the influence of analgesics used on cognitive function. Two months after the operation the degree of neuropathic pain will be evaluated with pain questionnaire. The data will be statistically evaluated.

Expected results: Participants with intraoperative infusion of lidocaine and dexmedetomidine will need less opioid analgesics during and after the operation in comparison to the group with fentanyl boluses only. The investigators expect better cognitive function after the operation in participants with dexmedetomidine infusion. Because of the minimal surgery injury to the peripheral nerves low incidence of neuropathic pain is expected in all groups.

Study design and methods Inclusion criteria: In our study the investigators will include patients aged 35 to 85, ASA 2-3 (according to the classification of American Society of Anesthesiologists), undergoing a planned laparoscopic intestine resection at the Department of Abdominal Surgery at the University Medical Centre Ljubljana. Included participants will sign the consensus for participating in the study after exact explanation and conversation, as well as consensus for anesthesia and surgery.

Exclusion criteria: Participants with allergies to alpha 2 receptor agonists, uncontrolled arterial hypertension, 2nd and 3rd degree atrioventricular block, alcohol and illegal drugs abusers, patients with clinically important neurological, cardiovascular, respiratory (COPD, emphysema), renal, liver, and gastrointestinal disease, will be excluded from our study. The investigators will also exclude pregnant women and patients younger than 18 years due to their physiological particularities.

Data collection: The participants will be prepared for the operation as usual according to the operative protocol. Cognitive function is going to be assessed with a mini mental test before the operation.

After inserting the peripheral venous line, the induction will be performed with analgesic fentanyl (2 mcg/kg) and sedative propofol (1,5-2,5 mg/kg). Muscle relaxant rocuronium will be used for easier intubation (0,6 mg/kg; standard dose). The participants will be controlled mechanically ventilated with tidal volumes 6-8 ml/kg. Anesthesia will be maintained with intravenous anesthetic propofol in doses between 4 - 6 mg/kg/h according to bispectral index value (bispectral index, BIS, Vista), which will be kept between 40 and 55, the interval suitable for surgical depth of anesthesia. Normothermia and normocapnia will be maintained. The fluids will be warmed to 39°C via Hotline, the body temperature and expired CO2 will be measured. Mean arterial blood pressure will be maintained within ± 25 % baseline value. When mean arterial blood pressure will decrease more than 25% from the baseline value, a bolus of a vasoactive drug will be used.

Beside the standard monitoring (electrocardiogram, pulse oximetry, indirect blood pressure management, capnometry), the investigators will use ANI (analgesia nociception index) monitoring for the pain measurement. ANI values will be maintained between 50 and 70 and between those valuse good analgesia is provided. Muscle relaxation will be measured with TOF (train of four) and will be maintained on the level of deep muscle relaxation, that is TOF 0 and PTC 1 - 2 (posttetanic count).

Before the operation the investigators will randomize the participants into the three groups, which will distinguish according to analgesia used. All participants will get intravenous bolus of fentanyl (2 mcg/kg, standard dose) before the incision. All of them will receive bolus of fentanyl when ANI will drop below 50 during the operation (2 mcg/kg, recommended standard dose, first group). Participants in the second group will receive infusion of lidocaine (1,5 mg/kg/h), and participants in the third group infusion of dexmedetomidine (0,5 µg/kg/h). The consumption of fentanyl and propofol will be measured during the operation. The infusion of lidocaine and dexmedetomidine will be stopped 10 minutes before the end of the operation. Propofol infusion will be stopped at the end of the final suture. After the operation all participants will receive postoperative infusion of piritramide delivered with PCA (patient control analgesia). If the pain according to the visual analog scale (VAS) will be more than 3, the participants will be given a bolus of the peripheral acting analgesic or opioid (paracetamol, metamizol, piritramide). VAS will be reevaluated two days after the operation, as well as the consumption of other opioids and other analgesics. Cognitive function will be evaluated again on the second day with mini mental test, or at the transfer of the participant to the surgical ward with the discontinuation of the opioids and when they will be afebrile. Neuropathic pain will be evaluated with the pain questionnaire two months after the operation.

Statistical analysis: Collected data will be presented using descriptive statistics such as mean, median and standard deviation. The use of the opioids and other analgesics will be compared using paired Student t-test or other suitable nonparametric tests (eg. ANOVA), depending on the type of data used.

Correlation of different factors will be determined using Pearson/Spearman correlation coefficient. Deviation from normal distribution of data will be tested with a chi-squared test. Predictive value will be determined using logistic regression.

Expected results: The investigators assume that there will be less opioid consumption in participants receiving lidocaine or dexmedetomidine infusion during the operation and the following two days compared to participants who received fentanyl boluses only. In participants with intraoperative infusion of dexmedetomidine the investigators expect preserved cognitive function. Low incidence of neuropathic pain is expected two months after the operation in all groups because of minimal peripheral nerve injury during operation.

Being tested
Dexmedetomidine, Lidocaine, placebo, Fentanyl
Keywords
dexmedetomidine, lidocaine, neuropathic pain, laparoscopic intestine resection, cognitive function
Medical subject headings
Opioid-Related Disorders, Neuralgia

What participants receive

What participants receive. In a randomised study each person is assigned to one group by chance.

  • DexmedetomidineDrug

    Also called Dexdor

    The participants will be given infusion of dexmedetomidine 0,5 mcg/kg/h intravenously.

  • LidocaineDrug

    Also called Xylocaine

    The participants will be given infusion of lidocaine 1,5 mg/kg/h intravenously.

  • placeboOther

    The participants will be given infusion of normal saline intravenously.

  • FentanylDrug

    Fentanyl 2 mcg/kg will be given to all participants for the intubation and during the operation when ANI value drops below 50.

Study groups in NCT02616523
Study groupRoleWhat they receive
dexmedetomidineActive comparatorThe investigators will compare fentanyl consumption in participants undergoing laparoscopic intestine resection intra and postoperatively. Dexmedetomidine group will receive dexmedetomidine infusion 0,5 mcg/kg/h beside boluses of fentanyl.
Receives: Drug: Dexmedetomidine; Drug: Fentanyl
lidocaineActive comparatorLidocaine group will receive lidocaine infusion 1,5 mg/kg/h during the laparoscopic intestine resection.
Receives: Drug: Lidocaine; Drug: Fentanyl
placeboPlacebo comparatorThe placebo group will receive intravenous infusion of normal saline only.
Receives: Other: placebo; Drug: Fentanyl

What is being measured

The primary outcome is the main question the study is designed to answer.

  1. Consumption of Fentanyl

    consumption of fentanyl (mg) during the procedure

    Measured: time of the operation

Secondary outcomes (2)
  1. Consumption of Piritramide

    consumption of piritramide (mg) in the recovery room

    Measured: one hour after the operation

  2. Neuropathic Pain (Pain Questionnaire) dn4

    Pain questionnaire dn4 will be send to participants after two months of surgery to evaluate the neuropathic pain. There are minimum 0 points and maximum 10 points. If the score is 4 or higher then the pain is likely to be neuropathic pain.

    Measured: two months after the surgery

Timeline

From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.

  1. First posted30 Nov 2015 (estimated)
  2. Study startJul 2014
  3. Primary completionJun 2015
  4. Study completionMay 2016

Resources

More details

For doctors and researchers: how the study is designed, who runs it, and its registry IDs.

Study design
Study type
Interventional
Phase
Phase 4
Primary purpose
Treatment
Allocation
Randomised
Intervention model
Parallel groups
Masking
Single blind
Who is masked
Participant
Enrolment
60 participants (actual)
IDs, dates and publications
ClinicalTrials.gov ID
NCT02616523
Sponsor's protocol ID
23/07/14
Status last verified
Aug 2016
First submitted
7 Nov 2015
Last updated
11 Oct 2016
Data monitoring committee
No

Publications

  • Vigneault L, Turgeon AF, Cote D, Lauzier F, Zarychanski R, Moore L, McIntyre LA, Nicole PC, Fergusson DA. Perioperative intravenous lidocaine infusion for postoperative pain control: a meta-analysis of randomized controlled trials. Can J Anaesth. 2011 Jan;58(1):22-37. doi: 10.1007/s12630-010-9407-0.

    PubMed 21061107
  • Koppert W, Weigand M, Neumann F, Sittl R, Schuettler J, Schmelz M, Hering W. Perioperative intravenous lidocaine has preventive effects on postoperative pain and morphine consumption after major abdominal surgery. Anesth Analg. 2004 Apr;98(4):1050-1055. doi: 10.1213/01.ANE.0000104582.71710.EE.

    PubMed 15041597
  • Gurbet A, Basagan-Mogol E, Turker G, Ugun F, Kaya FN, Ozcan B. Intraoperative infusion of dexmedetomidine reduces perioperative analgesic requirements. Can J Anaesth. 2006 Jul;53(7):646-52. doi: 10.1007/BF03021622.

    PubMed 16803911
  • Tufanogullari B, White PF, Peixoto MP, Kianpour D, Lacour T, Griffin J, Skrivanek G, Macaluso A, Shah M, Provost DA. Dexmedetomidine infusion during laparoscopic bariatric surgery: the effect on recovery outcome variables. Anesth Analg. 2008 Jun;106(6):1741-8. doi: 10.1213/ane.0b013e318172c47c.

    PubMed 18499604
  • Shin JH, Howard FM. Abdominal wall nerve injury during laparoscopic gynecologic surgery: incidence, risk factors, and treatment outcomes. J Minim Invasive Gynecol. 2012 Jul-Aug;19(4):448-53. doi: 10.1016/j.jmig.2012.03.009. Epub 2012 May 3.

    PubMed 22560041
  • Niccolai P, Ouchchane L, Libier M, Beouche F, Belon M, Vedrinne JM, El Drayi B, Vallet L, Ruiz F, Biermann C, Duchene P, Chirat C, Soule-Sonneville S, Duale C, Dubray C, Schoeffler P. Persistent neuropathic pain after inguinal herniorrhaphy depending on the procedure (open mesh v. laparoscopy): a propensity-matched analysis. Can J Surg. 2015 Apr;58(2):114-20. doi: 10.1503/cjs.008314.

    PubMed 25799247
  • Spindler Vesel A, Vrečar V, Repar A, Požar Lukanović N. Efficiency of PCA with piritramid and postoperative occurence of neuropathic pain in laparoscopic and clasical colorectal surgery. In: Della Roca G, De Monte A, eds. Proceedings of 25th Anesthesia And ICU Symposium Alpe-Adria. Udine, 2012:90-3.

  • Deiner S, Silverstein JH. Postoperative delirium and cognitive dysfunction. Br J Anaesth. 2009 Dec;103 Suppl 1(Suppl 1):i41-46. doi: 10.1093/bja/aep291.

    PubMed 20007989
  • Jeanne M, Logier R, De Jonckheere J, Tavernier B. Heart rate variability during total intravenous anesthesia: effects of nociception and analgesia. Auton Neurosci. 2009 May 11;147(1-2):91-6. doi: 10.1016/j.autneu.2009.01.005. Epub 2009 Feb 8.

    PubMed 19201661
  • Penney R. Use of dexmedetomidine and ketamine infusions during scoliosis repair surgery with somatosensory and motor-evoked potential monitoring: a case report. AANA J. 2010 Dec;78(6):446-50.

    PubMed 21309291
  • Feld JM, Hoffman WE, Stechert MM, Hoffman IW, Ananda RC. Fentanyl or dexmedetomidine combined with desflurane for bariatric surgery. J Clin Anesth. 2006 Feb;18(1):24-8. doi: 10.1016/j.jclinane.2005.05.009.

    PubMed 16517328
  • McCarthy GC, Megalla SA, Habib AS. Impact of intravenous lidocaine infusion on postoperative analgesia and recovery from surgery: a systematic review of randomized controlled trials. Drugs. 2010 Jun 18;70(9):1149-63. doi: 10.2165/10898560-000000000-00000.

    PubMed 20518581
  • Andjelkovic L, Novak-Jankovic V, Pozar-Lukanovic N, Bosnic Z, Spindler-Vesel A. Influence of dexmedetomidine and lidocaine on perioperative opioid consumption in laparoscopic intestine resection: a randomized controlled clinical trial. J Int Med Res. 2018 Dec;46(12):5143-5154. doi: 10.1177/0300060518792456. Epub 2018 Sep 13.

    PubMed 30209962

Questions about this trial

What is this clinical trial studying?

A Phase 4 study testing Dexmedetomidine, Lidocaine and Fentanyl in people with Opioid-Related Disorders and Neuralgia, run by University Medical Centre Ljubljana.

The full registered description is in the About this study section and the official record.

Who may be eligible to take part?

The sponsor lists 3 inclusion and 7 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.

Is this clinical trial currently recruiting?

The record says: finished, as of the sponsor's last update on 11 Oct 2016. Status can change between updates, so confirm with the study contact before making plans.

What are the possible benefits and risks?

They depend on the study and the treatment, and no study can promise a benefit. Some participants in this study may receive a placebo. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.

What does this phase mean?

Phase 4 studies take place after a treatment is approved, to learn more about its long-term benefits and risks in everyday use.

Not every study follows the same path, and some studies (observational studies, device studies) have no phase.

Are results available for this study?

Yes. Results are posted in the registry (first posted 11 Jul 2016). A summary is in the For doctors view, and the full results are on ClinicalTrials.gov.

How can a doctor refer a patient or contact the research team?

The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.

What does the primary outcome measure?

Consumption of Fentanyl (time frame: time of the operation). It is what the study was designed to measure, not a finding.

Where can I read the original study information?

On the ClinicalTrials.gov record for NCT02616523, which also lists 13 linked publications.

Does a listing mean the treatment is approved or proven to work?

No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.

How often is this information updated?

AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 11 Oct 2016.

Free account

Log in to keep searching

You’ve used your 3 free searches. AzTrials is free: log in or create a free account to keep searching clinical trials and save the ones you want to follow.

Create a free accountLog in